Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia

References

• American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH)2010Chapter 1: Guideline on the management of benign prostatic hyperplasia (BPH) Available from: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph. Accessed May 13, 2011
   Google Scholar
• WassermanNFBenign prostatic hyperplasia: A review and ultrasound classificationRadiol Clin North Am20064468971017030221
   PubMed Web of Science ®Google Scholar
• ThorpeANealDBenign prostatic hyperplasiaLancet20033611359136712711484
   PubMed Web of Science ®Google Scholar
• RoehrbornCGMcConnellJDBenign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural historyWeinAJKavoussiLRNovickACCampbell-Walsh Urology9th edPhiladelphia, PAWB Saunders2007
   Google Scholar
• EmbertonMCornelEBBassiPFBenign prostatic hyperplasia as a progressive disease: A guide to the risk factors and options for medical managementInt J Clin Pract2008621076108618479366
   PubMed Web of Science ®Google Scholar
• FineSRGinsbergPAlpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: Issues and potential complicationsJ Am Osteopath Assoc200810833333718648026
   PubMedGoogle Scholar
• BeduschiMCBeduschiROesterlingJEAlpha-blockade therapy for benign prostatic hyperplasia: From a nonselective to a more selective alpha1A-adrenergic antagonistUrology1998518618729609620
   PubMed Web of Science ®Google Scholar
• O’LearyMPLower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complicationsUrology200362Suppl 1152312957196
   PubMed Web of Science ®Google Scholar
• EdwardsJLDiagnosis and management of benign prostatic hyperplasiaAm Fam Physician2008771403141018533373
   PubMed Web of Science ®Google Scholar
• SchwinnDARoehrbornCGAlpha1-adrenoceptor subtypes and lower urinary tract symptomsInt J Urol20081519319918304211
   PubMed Web of Science ®Google Scholar
• HiebleJPBylundDBClarkeDEInternational Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus updatePharmacol Rev1995472672707568329
   PubMed Web of Science ®Google Scholar
• SchwinnDAJohnstonGIPageSOCloning and pharmacological characterization of human alpha-1 adrenergic receptors: Sequence corrections and direct comparison with other species homologuesJ Pharmacol Exp Ther19952721341427815325
   PubMed Web of Science ®Google Scholar
• HawrylyshynKAMichelottiGACogeFUpdate on human alpha1-adrenoceptor subtype signaling and genomic organizationTrends Pharmacol Sci20042544945515559245
   PubMed Web of Science ®Google Scholar
• PriceDTLefkowitzRJCaronMGLocalization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: Implications for human alpha-adrenergic physiologyMol Pharmacol1994451711758114668
   PubMed Web of Science ®Google Scholar
• PriceDTSchwinnDALomasneyJWIdentification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostateJ Urol19931505465517686987
   PubMed Web of Science ®Google Scholar
• AnderssonKELeporHWyllieMGProstatic alpha 1-adrenoceptors and uroselectivityProstate1997302022159122046
   PubMed Web of Science ®Google Scholar
• PriceDTSchwinnDALomasneyJWAllenLFCaronMGLefkowitzRJIdentification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostateJ Urol19931505465517686987
   PubMed Web of Science ®Google Scholar
• NasuKMoriyamaNFukasawaRQuantification and distribution of α1-adrenoceptor subtype mRNAs in human proximal urethraBr J Pharmacol1998123128912939579721
   PubMed Web of Science ®Google Scholar
• RudnerXLBerkowitzDEBoothJVSubtype specific regulation of human vascular α1-adrenergic receptors by vessel bed and ageCirculation19991002336234310587338
   PubMed Web of Science ®Google Scholar
• SouvereinPCVan StaaTPEgbertsACGDe la RosetteJJMHCooperCLeufkensHGUse of α-blockers and the risk of hip/femur fracturesJ Int Med2003254548554
   PubMed Web of Science ®Google Scholar
• ShibataKFoglarRHorieKKMD-3213, a novel, potent, α1A-adrenoceptor-selective antagonist: characterization using recombinant human α1-adrenoceptors and native tissuesMol Pharmacol1955482502587651358
   PubMed Web of Science ®Google Scholar
• YamazakiYDevelopment of silodosinYakugaku Zasshi2006126207208
   Web of Science ®Google Scholar
• TatemichiSKobayashiKMaezawaMα1-Adrenoceptor subtype selectivity and organ specificity of Silodosin (KMD-3213)Yakugaku Zasshi200612620921616518085
   PubMed Web of Science ®Google Scholar
• IshiguroMFutabayashiYOhnukiTAhmedMMuramatsuINagatomoTIdentification of binding site of prazosin, tamsulosin, and KMD-3213 with α1–adreneergic receptor subtypes by molecular modelingLife Sci2002712531254112270758
   PubMed Web of Science ®Google Scholar
• TatemichiSKobayashiKMaruyamaIEffects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats – study of the selectivity for lower urinary tractYakugaku Zasshi200612621722316518086
   PubMed Web of Science ®Google Scholar
• AkiyamaKHoraMTatemichiSKMD-3213, a uroselective and long-acting α1a-adrenoceptor antagonist, tested in a novel rat modelJ Pharmacol Exp Ther1999291819110490890
   PubMed Web of Science ®Google Scholar
• KawabeKYoshidaMHommaYSilodosin, a new α1A-adrenoceptor selective antagonist for treating benign prostatic hyperplasia: Results of a Phase III randomized, placebo-controlled, double-blind study in Japanese menBJU Int2006981019102416945121
   PubMed Web of Science ®Google Scholar
• MarksLSGittelmanMCHillLAVolinnWHoelGRapid efficacy of the highly selective alpha1 A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 Phase III studiesJ Urol20091812634264019371887
   PubMed Web of Science ®Google Scholar
• ChappleCRMontorsiFTammelaTJWirthMKoldewijnEFernandezEFEuropean Silodosin Study GroupSilodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in EuropeEur Urol20115934235221109344
   PubMed Web of Science ®Google Scholar
• KawabeKYoshidaMArakawaSTakeuchiHSilodosin Clinical Study GroupLong-term evaluation of silodosin, a new α1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia: Phase III long-term studyJap J Urol Surg200619153164
   Google Scholar
• MarksLSGittelmanMCHillLAVolinnWHoelGSilodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: A 9-month, open-label extension studyUrology2009741318132219815265
   PubMed Web of Science ®Google Scholar
• YamanishiTMizunoTTatsumiyaKWatanabeMKamaiTYoshidaKUrodynamic effects of silodosin, a new α1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasiaNeurourol Urodyn20102955856219693954
   PubMed Web of Science ®Google Scholar
• MatsukawaYGotohMKomatsuTFunahashiYSassaNHattoriREfficacy of silodosin for relieving benign prostatic obstruction: Prospective pressure flow studyJ Urol20091822831283519837428
   PubMed Web of Science ®Google Scholar
• MiyakitaHYokoyamaEOnoderaYShort-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasiaInt J Urol20101786987520735791
   PubMed Web of Science ®Google Scholar
• MichelMCα1-Adrenoceptors and ejaculatory functionBr J Pharmacol200715228929017603543
   PubMed Web of Science ®Google Scholar
• KobayashiKMasumoriNHisasueSInhibition of seminal emission is the main cause of an ejaculation induced by a new highly selective α1A-blocker in normal volunteersJ Sex Med200852185219018399947
   PubMed Web of Science ®Google Scholar
• SchulmanCCLower urinary tract symptoms/benign prostatic hyperplasia: Minimizing morbidity caused by treatmentUrology200362Suppl 3A243312957197
   PubMed Web of Science ®Google Scholar
• SanbeATanakaYFujiwaraYα1-Adrenoceptors are required for normal male sexual functionBr J Pharmacol200715233234017603545
   PubMed Web of Science ®Google Scholar
• HisasueSFuruyaRItohNKobayashiKFuruyaSTsukamotoTEjaculatory disorder caused by alpha-1adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emissionInt J Urol2006131311131617010010
   PubMed Web of Science ®Google Scholar
• RoehrbornCGKaplanSALeporHVolinnWSymptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPHProstate Cancer Prostatic Dis20111414314821135869
   PubMed Web of Science ®Google Scholar
• HommaYKawabeKTakedaMYoshidaMEjaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasiaUrology2010761446145020472263
   PubMed Web of Science ®Google Scholar
• AvisarRWeinbergerDIntraoperative floppy iris syndrome: Possible relationship with α1-adrenergic receptor antagonistsIsr Med Assoc J200911424419344012
   PubMed Web of Science ®Google Scholar
• OshikaTOhashiYInamuraMIncidence of intraoperative floppy iris syndrome in patients on either systemic or topical α1-adrenoceptor antagonistAm J Ophthalmol200714315015117188051
   PubMed Web of Science ®Google Scholar
• United State Food and Drug Administration/Center for Drug Evaluation and ResearchDrug Approval Package, RAPAFLO (silodosin) capsules, Application No. 022206 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000TOC.cfm. Accessed on April 1, 2011
   Google Scholar